Trial reportThe Journal of clinical endocrinology and metabolism2014
5α-reductase type 1 modulates insulin sensitivity in men.
Trial report in The Journal of clinical endocrinology and metabolism, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 85 citations in OpenAlex.
- Co-administration of 5α-reductase Inhibitors Worsens the Adverse Metabolic Effects of Prescribed Glucocorticoids.The Journal of clinical endocrinology and metabolism · 2020Trial
- Aromatase Inhibition Reduces Insulin Sensitivity in Healthy Men.The Journal of clinical endocrinology and metabolism · 2016Trial
- Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man.The Journal of clinical endocrinology and metabolism · 2016Trial
- Diet-induced weight loss has chronic tissue-specific effects on glucocorticoid metabolism in overweight postmenopausal women.International journal of obesity (2005) · 2015Trial
- Absence of Interaction Between 5α-Reductase Inhibitors and Glucocorticoids on Incidence of Myocardial Infarction in People With Type 2 Diabetes.Diabetes, obesity & metabolism · 2026Article
- Steroid 5α-reductases in the brain: From neurosteroidogenesis to therapeutic implications.Frontiers in neuroendocrinology · 2026Review
- Risk of Type 2 Diabetes Mellitus in New Users of 5-Alpha Reductase Inhibitors: A Nationwide Historical Cohort Study.Yonsei medical journal · 2026Article
- Cardiovascular safety of 5α-reductase inhibitors in people with benign prostatic hyperplasia and type 2 diabetes: a propensity score-matched analysis.European heart journal. Cardiovascular pharmacotherapy · 2026Article
- Metabolic Messengers: testosterone.Nature metabolism · 2026Review
- Risk of poor glycemic control in tamsulosin versus finasteride users with type 2 diabetes mellitus.Heliyon · 2025Article
- Circulating levels of blood biomarkers and risk of benign prostatic hyperplasia: Results from two large cohorts in Europe and East Asia.Journal of global health · 2024Article
- Metabolic benefits afforded by estradiol and testosterone in both sexes: clinical considerations.The Journal of clinical investigation · 2024Review
- Risks and side effects in the medical management of benign prostatic hyperplasia.Prostate international · 2024Review
- Is There an Association between 5a Reductase Inhibitors and Metabolic Syndrome? A Narrative Review of the Literature.Reviews on recent clinical trials · 2024Review
- AKR1D1 knockout mice develop a sex-dependent metabolic phenotype.The Journal of endocrinology · 2022Article
- Altered Steroidome in Women with Gestational Diabetes Mellitus: Focus on Neuroactive and Immunomodulatory Steroids from the 24th Week of Pregnancy to Labor.Biomolecules · 2021Article
- The association of new-onset diabetes mellitus and medical therapy for benign prostatic hyperplasia: A population-based study.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2021Article
- Recent Update on the Molecular Mechanisms of Gonadal Steroids Action in Adipose Tissue.International journal of molecular sciences · 2021Review
- Article
- Derivatization with 2-hydrazino-1-methylpyridine enhances sensitivity of analysis of 5α-dihydrotestosterone in human plasma by liquid chromatography tandem mass spectrometry.Journal of chromatography. A · 2021Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
context5α-Reductase (5αR) types 1 and 2 catalyze the A-ring reduction of steroids, including androgens and glucocorticoids. 5α-R inhibitors lower dihydrotestosterone in benign prostatic hyperplasia; finasteride inhibits 5αR2, and dutasteride inhibits both 5αR2 and 5αR1. In rodents, loss of 5αR1 promotes fatty liver.
objectiveOur objective was to test the hypothesis that inhibition of 5αR1 causes metabolic dysfunction in humans. DESIGN, SETTING, AND
participantsThis double-blind randomized controlled parallel group study at a clinical research facility included 46 men (20-85 years) studied before and after intervention.
interventionOral dutasteride (0.5 mg daily; n = 16), finasteride (5 mg daily; n = 16), or control (tamsulosin; 0.4 mg daily; n = 14) was administered for 3 months.
main outcome measureGlucose disposal was measured during a stepwise hyperinsulinemic-euglycemic clamp. Data are mean (SEM).
resultsDutasteride and finasteride had similar effects on steroid profiles, with reduced urinary androgen and glucocorticoid metabolites and reduced circulating DHT but no change in plasma or salivary cortisol. Dutasteride, but not finasteride, reduced stimulation of glucose disposal by high-dose insulin (dutasteride by -5.7 [3.2] μmol/kg fat-free mass/min, versus finasteride +7.2 [3.0], and tamsulosin +7.0 [2.0]). Dutasteride also reduced suppression of nonesterified fatty acids by insulin and increased body fat (by 1.6% [0.6%]). Glucose production and glycerol turnover were unchanged. Consistent with metabolic effects of dutasteride being mediated in peripheral tissues, mRNA for 5αR1 but not 5αR2 was detected in human adipose tissue.
conclusionDual inhibition of 5αRs, but not inhibition of 5αR2 alone, modulates insulin sensitivity in human peripheral tissues rather than liver. This may have important implications for patients prescribed dutasteride for prostatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.